Robert, this apparently was driving the move. Just found it.
Home - Yahoo! - Help
[ Business | US Market | By Industry | IPO | AP | S&P | International | PRNews | BizWire ]
Wednesday December 23, 10:55 am Eastern Time
Company Press Release
COR Therapeutics CEO Vaughn Kailian
talks to The Wall Street Transcript
NEW YORK--(BUSINESS WIRE)--Dec. 23, 1998--The Wall Street
Transcript has published an in-depth interview with Vaughn M. Kailian of
COR Therapeutics, Inc. (Nasdaq:CORR - news), in which he talks at
length about his company's future.
He says, ''COR Therapeutics is a biotechnology company whose activities are focused on developing drugs and
therapeutics for the treatment of severe cardiovascular diseases. The company is about ten years old. We have about
300 hundred employees, including our sales force. And we currently have one product, INTEGRILIN (tm), which is
being commercialized by us and our partner, Schering-Plough, in the United States.''
He explains, ''We have had INTEGRILAN (tm) on the market since July, and our joint sales forces have been
promoting it at full strength since September. We are already stocked in over 800 hospitals in the United States, and
well over 60 percent of those have the product on their formularies.''
Looking forward, he states, ''We're working on an oral blocker of the same receptor. INTEGRILAN (tm) is given
intravenously, and it's a very potent inhibitor of a receptor which is called GPIIB-IIIA that allows platelets to stick
together and form a clot as they clump up. We're also working on an oral product, a tablet that can be taken orally to
treat these same patients after they get released from the hospital and are susceptible to recurring chest pain or heart
attacks. Also, we hope this product can be taken to prevent an occurrence from happening in the first place. So the
markets do not overlap with the INTEGRILAN(tm) market and really serve to expand the number of severe
cardiovascular patients that we're aiming to treat.''
To read the complete interview, go to twst.com. It requires Adobe Acrobat (tm) reader to
view the document. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock
recommendations.
The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 35
years. The Transcript publishes industry roundtables and interviews with Wall Street analysts, money managers, and
Company CEOs, and is read by top money managers, brokers, and individual investors. For subscription information
call (800) 246-7673.
Contact:
The Wall Street Transcript, twst.com
Barbara Diliberti (212) 952-7455
Related News Categories: medical/pharmaceutical, publishing
Help
Copyright © 1998 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of
copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these
materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving ina public database, redistributing via a
computer network or in a printed form.
See our Important Disclaimers and Legal Information.
Questions or Comments? |
